PolyPeptide Group Shares Climb After Report of Takeover Interest

By Adria Calatayud

PolyPeptide Group shares rose after a Bloomberg report that the Swiss contract drug manufacturer attracted takeover interest from private-equity groups including Sweden's EQT and New York-based KKR.

Shares in PolyPeptide climbed 16%, in a session with broad-based losses across European stocks due to the conflict in the Middle East. The rise took the stock's year-to-date gain to around 40%.

Potential suitors are still considering a possible acquisition and there is no certainty that their deliberations would lead to a deal, according to Bloomberg.

PolyPeptide and EQT didn't respond to requests for comment. KKR declined to comment.

The ownership of PolyPeptide--in which a foundation controlled by businessman Frederik Paulsen Jr. holds a 56.10% stake--means any potential private-equity buyer might need to seek a joint ownership model, analysts at RBC Capital Markets wrote in a note to clients.

Write to Adria Calatayud at [e-mail]

(END) Dow Jones Newswires

04-13-26 0424ET